(12) STANDARD PATENT (11) Application No. AU 2018203056 B2 (19) AUSTRALIAN PATENT OFFICE
Total Page:16
File Type:pdf, Size:1020Kb
(12) STANDARD PATENT (11) Application No. AU 2018203056 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF (51) International Patent Classification(s) C07D 231/12 (2006.01) A61P 37/00 (2006.01) A61K 31/415 (2006.01) C07D 401/04 (2006.01) A61K 31/4155 (2006.01) C07D 403/08 (2006.01) A61P 3/00 (2006.01) C07D 405/04 (2006.01) A61P 9/00 (2006.01) C07D 405/08 (2006.01) A61P 25/00 (2006.01) C07D 405/12 (2006.01) A61P 35/00 (2006.01) C07D 493/10 (2006.01) (21) Application No: 2018203056 (22) Date of Filing: 2018.05.02 (43) Publication Date: 2018.07.19 (43) Publication Journal Date: 2018.07.19 (44) Accepted Journal Date: 2020.05.21 (62) Divisional of: 2014236146 (71) Applicant(s) Epizyme, Inc. (72) Inventor(s) Shapiro, Gideon;Chesworth, Richard;Mitchell, Lorna Helen;Swinger, Kerren Kalai (74) Agent / Attorney Pizzeys Patent and Trade Mark Attorneys Pty Ltd, PO Box 291, WODEN, ACT, 2606, AU (56) Related Art CAS Registry Number 1342545-59-8; STN Entry Date 08 November 2011; 1,2 Ethanediamine, N,N2-dimethyl-N1-[(1,3,5-trimethyl-1H-pyrazol-4- yl)methyl] CAS Registry Number 1340581-60-3; STN Entry Date 03 November 2011; 1,2 Ethanediamine, N1-[(5-chloro-1,3-dimethyl-1H-pyrazol-4- yl)methyl]-N1,N2 dimethyl CAS Registry Number 1250565-99-1; STN Entry Date 03 November 2010; 1,2 Ethanediamine, N-methyl-N-[(1,3,5-trimethyl-1H-pyrazol-4-yl)methyl]- ABSTRACT Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using the compounds for treating arginine methyltransferase-mediated disorders are also described. WO 2014/153226 PCT/US2014/029710 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Related Applications [0001] The present application claims priority under 35 U.S.C. § 119(e) to U.S. provisional patent applications, U.S.S.N. 61/781,051, filed March 14, 2013, and U.S.S.N. 61/876,034 filed September 10, 2013, the entire contents of which is incorporated herein by reference. Background of the Invention [0002] Epigenetic regulation of gene expression is an important biological determinant of protein production and cellular differentiation and plays a significant pathogenic role in a number of human diseases. [0003] Epigenetic regulation involves heritable modification of genetic material without changing its nucleotide sequence. Typically, epigenetic regulation is mediated by selective and reversible modification (e.g., methylation) of DNA and proteins (e.g., histones) that control the conformational transition between transcriptionally active and inactive states of chromatin. These covalent modifications can be controlled by enzymes such as methyltransferases (e.g., arginine methyltransferases), many of which are associated with specific genetic alterations that can cause human disease. [0004] Disease-associated chromatin-modifying enzymes (e.g., arginine methyltransferases) play a role in diseases such as proliferative disorders, autoimmune disorders, muscular disorders, vascular disorders, metabolic disorders, and neurological disorders. Thus, there is a need for the development of small molecules that are capable of inhibiting the activity of arginine methyltransferases. Detailed Description of Certain Embodiments [0005] Arginine methyltransferases are attractive targets for modulation given their role in the regulation of diverse biological processes. It has now been found that compounds described herein, and pharmaceutically acceptable salts and compositions thereof, are effective as inhibitors of arginine methyltransferases. Such compounds have the general Formula (I): 1/379 WO 2014/153226 PCT/US2014/029710 HN-R 3 R LX N 3 or a pharmaceutically acceptable salt thereof, wherein X, Y, Z, L1 , Rw, R , and R are as defined herein. [0006] In some embodiments, pharmaceutical compositions are provided which comprise a compound described herein (e.g., a compound of Formula (I)), or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable excipient. [0007] In certain embodiments, compounds described herein inhibit activity of an arginine methyltransferase (RMT) (e.g., PRMT1, PRMT3, CARMI, PRMT6, and/or PRMT8). In certain embodiments, methods of inhibiting an arginine methyltransferase are provided which comprise contacting the arginine methyltransferase with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof. The RMT may be purified or crude, and may be present in a cell, tissue, or a subject. Thus, such methods encompass inhibition of RMT activity both in vitro and in vivo. In certain embodiments, the RMT is wild-type. In certain embodiments, the RMT is overexpressed. In certain embodiments, the RMT is a mutant. In certain embodiments, the RMT is in a cell. In some embodiments, the RMT is expressed at normal levels in a subject, but the subject would benefit from RMT inhibition (e.g., because the subject has one or more mutations in an RMT substrate that causes an increase in methylation of the substrate with normal levels of RMT). In some embodiments, the RMT is in a subject known or identified as having abnormal RMT activity (e.g., overexpression). [0008] In certain embodiments, methods of modulating gene expression in a cell are provided which comprise contacting a cell with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In certain embodiments, the cell in culture in vitro. In certain embodiments, cell is in an animal, e.g., a human. [0009] In certain embodiments, methods of modulating transcription in a cell are provided which comprise contacting a cell with an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In certain embodiments, the cell in culture in vitro. In certain embodiments, the cell is in an animal, e.g., a human. 2/379 WO 2014/153226 PCT/US2014/029710 [0010] In some embodiments, methods of treating an RMT-mediated disorder (e.g., a PRMT1-, PRMT3-, CARM1-, PRMT6-, or PRMT8-mediated disorder) are provided which comprise administering to a subject suffering from an RMT-mediated disorder an effective amount of a compound described herein (e.g., a compound of Formula (I)), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof. In certain embodiments, the RMT-mediated disorder is a proliferative disorder. In certain embodiments, compounds described herein are useful for treating cancer. In certain embodiments, compounds described herein are useful for treating breast cancer, prostate cancer, lung cancer, colon cancer, bladder cancer, or leukemia. In certain embodiments, the RMT-mediated disorder is a muscular disorder. In certain embodiments, the RMT-mediated disorder is an autoimmune disorder. In certain embodiments, the RMT-mediated disorder is a neurological disorder. In certain embodiments, the RMT-mediated disorder is a vascular disorder. In certain embodiments, the RMT-mediated disorder is a metabolic disorder. [0011] Compounds described herein are also useful for the study of arginine methyltransferases in biological and pathological phenomena, the study of intracellular signal transduction pathways mediated by arginine methyltransferases, and the comparative evaluation of new RMT inhibitors. [0012] This application refers to various issued patent, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. [0013] Definitions of specific functional groups and chemical terms are described in more detail below. The chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 7 5th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987. [0014] Compounds described herein can comprise one or more asymmetric centers, and thus can exist in various isomeric forms, e.g., enantiomers and/or diastereomers. For example, the compounds described herein can be in the form of an individual enantiomer, diastereomer or geometric isomer, or can be in the form of a mixture of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomer. Isomers can 3/379 WO 2014/153226 PCT/US2014/029710 be isolated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers can be prepared by asymmetric syntheses. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (E.L. Eliel,